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Purpose: Ovarian cancer has a poor prognosis, yet pathologic and clinical data do not accurately
predict which patients will ultimately succumb to their disease. We previously reported an
association between rs61764370, a germline functional variant in the 3’UTR of the KRAS
oncogene, and epithelial ovarian cancer (EOC) risk. Here we evaluate this variant as a biomarker
of clinical outcome and chemotherapy resistance in EOC.
Patients and Methods: Four groups of EOC patients with complete clinical data were genotyped
for the KRAS-variant and analyzed: Sporadic EOC patients (n=451); BRCA mutant EOC patients
(n=79); EOC patients treated with neoadjuvant chemotherapy (n=122), and; EOC patients treated
adjuvantly with platinum-based chemotherapy after cytoreductive surgery (n=292).
Results: The KRAS-variant predicts for significantly worse survival for EOC patients over 55
years-old by multivariate Cox regression analysis (HR=1.71, 95% CI=1.09 – 2.69, p = 0.02).
However, for the subgroup of EOC patients with known BRCA mutations, the KRAS-variant did
not predict altered outcome (HR=0.994, CI=0.28-3.56, p=0.99). KRAS-variant positive EOC
patients respond poorly to neoadjuvant carboplatin and paclitaxel chemotherapy, having
significantly more residual disease remaining after surgery (OR=26.27, CI=1.56- 441.83,
p=0.0232). In addition, EOC patients that harbor the KRAS-variant are more likely to be resistant
to adjuvant platinum chemotherapy (OR=2.86, CI=1.13-7.23, p=0.026).
Conclusions: These findings expand the potential importance of the KRAS-variant in EOC, from
acting as a marker of risk to being a biomarker that predicts worse outcome, perhaps due to its
association with platinum resistance. These data may ultimately help lead to treatment
optimization and improved outcome for KRAS-variant positive EOC patients.
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Introduction
Ovarian cancer is the 5th leading cause of cancer deaths in women. In 2010 there
were 21,880 new cases and 13,850 deaths (1). Early symptoms are vague, and
approximately 75% of patients have stage III or stage IV disease at the time of diagnosis.
For those patients with ovarian adenocarcinoma, the 5 year survival rate is 37% for those
with stage III disease and 25% for those with stage IV disease (2). Randomized trials
conducted by the Gynecologic Oncology Group have demonstrated that prognosis
worsens in epithelial ovarian cancer with older age, higher grade, higher stage, and
malignant cytology (3). Serial monitoring of CA-125 levels is currently used in patient
follow-up, but is not without controversy given its low sensitivity in early disease (4). As
such, further identification and study of molecular markers is key to providing a more
thorough assessment of cancer risk, patient prognosis and response to therapy.

Demographics
Although the incidence of ovarian cancer is lower than the incidence of uterine
cancer (12.9 cases per 100,000 women per year vs. 23.5 cases per 100,000 women per
year, respectively), ovarian cancer is the deadliest gynecologic malignancy (5). Indeed,
the 5-year survival rate for patients diagnosed between 1999 and 2006, regardless of
stage, was 45.6% in ovarian cancer compared to 82.7% in uterine cancer. This difference
is at least in part attributable to the stage at diagnosis, as 62% of ovarian cancer patients
have metastatic disease at the time of diagnosis, while only 8% of uterine cancer patients
present with metastatic disease (5). Among patients with ovarian cancer, older age,

1

advanced stage at diagnosis, ascites volume, and the amount of residual disease were all
significant predictors of reduced overall survival (6).
As recorded by the SEER database the median age of diagnosis of ovarian cancer
is 63 years-old, and 68.6% presented over the age of 55. Although ovarian cancer affects
all ethnicities, it is most common among Caucasian patients and least common in Asian
women (13.5 cases vs. 9.8 cases per 100,000 women per year, respectively) (5).

BRCA Mutations
Approximately 10 – 15% of ovarian cancers occur in patients with BRCA1/2
mutations (7) (8). There is a higher risk of ovarian cancer in BRCA1 patients. By age 70,
the average risk of diagnosis ranges from 40 – 60 % in BRCA1 patients (9) (10). By
contrast, in BRCA2 patients, the average risk of diagnosis ranges from 11 - 27% by age
70 (11) (12). BRCA1 patients also tend to be younger at the time of diagnosis (7).
Up to 40% of Ashkenazi Jewish patients with epithelial ovarian cancer are
estimated to carry a BRCA1 or BRCA2 mutation (13). Ashkenazi Jewish women with a
BRCA1 or BRCA2 mutation have a 16% risk of ovarian cancer diagnosis by age 70 (14).

Diagnosis
As previously noted, over 75% of ovarian cancer patients present with stage III or
stage IV disease. Survival declines significantly with advanced stage. Five-year survival
rates for patients who are treated with cytoreductive surgery and chemotherapy are as
follows: 93% in stage I disease; 70% in stage II disease; 37% in stage III disease; and
25% in stage IV disease (2). In the majority of cases there is a delay of at least four
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months from symptom onset to presentation to a physician (15) (16) (17). Indeed, a
survey of 1725 ovarian cancer patients by Goff et al reported that 95% of patients
experienced symptoms prior to diagnosis. The most common symptoms were: abdominal,
such as increased abdominal size or bloating; gastrointestinal, such as nausea,
indigestion, or constipation; and pain. Symptoms were not limited to patients with
advanced disease at the time of diagnosis, as 89% of patients with stage I or II disease
reported symptoms, compared to 97% of patients with stage III or IV disease (18).
A higher number of symptoms was significantly associated with a delay in
diagnosis (mean of 2.0 months from presentation to diagnosis in patients with 2
symptoms vs. 10.7 months in patients with 6 or more symptoms, p = 0.001), as well as
younger age (mean age of 53 years old in patients with 2 symptoms vs. 46 years old in
patients with 6 or more symptoms, p = 0.001) and a treatment for an incorrect diagnosis
(21% of patients with 2 symptoms vs. 50% of patients with 6 or more symptoms, p =
0.001). Of note, patients who were diagnosed earlier were significantly more likely to
have received diagnostic tests such as a pelvic exam, abdominal pelvic CT scan, and CA125 levels.
Diagnosis is also complicated by the vague nature of the symptoms. A
prospective case-control study consisting of 1709 control patients and 128 patients with a
pelvic mass demonstrated that many patients who do not have cancer may report similar
symptoms. However, patients with cancer were more likely to have a higher median
number of symptoms (8 symptoms vs. 4 symptoms in control patients). There was also a
significant difference in the median number of recurring symptoms (4 symptoms in
cancer patients vs. 2 symptoms in control patients, p = 0.01) (19).
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Patients in the survey by Goff et al were diagnosed by family practitioners,
internists, or obstetrician-gynecologists. While there was no significant difference in
mean time to diagnosis between these specialties, obstetrician-gynecologists were
significantly more likely to diagnose patients with stage I or stage II disease compared to
family practitioners or internists. Indeed, 29% of patients diagnosed by obstetriciangynecologists had stage I or stage II disease compared to 18% of patients seen by family
practitioners or internists (p = 0.009). A retrospective review of 533 ovarian cancer
patients also found that overall survival increased when patients saw a gynecologist first
(p < 0.05) (20). This difference may be due to initial interventions, as obstetriciangynecologists were also more likely to perform a pelvic exam and order other diagnostic
tests, such as CA-125 levels. For example, a pelvic exam was performed on 94% of
patients seen by an obstetrician-gynecologist compared to 50% seen by a family
practitioner and 43% seen by an internist, p = 0.001 (18).

Treatment
The standard treatment for epithelial ovarian cancer consists of cytoreductive
surgery, which includes surgical staging, and a platinum-based chemotherapy regimen.

Surgery
Surgical staging and pathology results are key to an accurate diagnosis and will
also influence treatment decisions and prognosis (21) (22) (23). A prospective
randomized trial demonstrated that patients who had cytoreductive surgery after receiving
three cycles of platinum based chemotherapy had improved overall and progression-free
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survival compared to patients who only received chemotherapy (24). Furthermore,
patients who have optimal cytoreduction at the time of surgery, which is typically defined
as residual tumor mass less than or equal to 1 cm in diameter, have improved overall
survival (25) (26) (27) (28). A meta-analysis consisting of 81 cohorts containing a total
of 6,885 patients with stage III or stage IV disease showed a statistically significant
correlation between the degree of cytoreduction and the log median survival time
(p<0.001). This correlation remained statistically significant even after controlling for
factors such as patient age, disease stage at diagnosis, and platinum dose-intensity (27).

Chemotherapy
The standard chemotherapy regimen for epithelial ovarian cancer is a platinumcontaining agent in combination with another drug, such as a taxane. The most common
regimen currently used to treat EOC is carboplatin and paclitaxel (29) (30).
Cisplatin was approved by the FDA for use in ovarian cancer in 1978 (31). An
early trial demonstrated improved response rates and progression-free survival with
cisplatin combination therapies; however there were no significant differences in overall
survival (32). In a larger trial by O’Mura et al containing 440 patients treated with
doxorubicin and cyclophosphamide with or without cisplatin, those patients with palpable
disease at the start of the trial who received cisplatin had improved progression-free and
overall survival. However, when survival results for patients with non-palpable disease
were combined with patients with palpable disease, the difference in survival was not
significant (33). These studies were complicated by their recruitment, in that cisplatin
based therapies were used primarily as salvage therapy, instead of first-line treatment.

5

While the use of cisplatin increased in ovarian cancer, it was also associated with
significant toxicity, including nephrotoxicity, neurotoxicity and gastrointestinal distress.
As such, the development of carboplatin in the 1980s represented an important new
treatment option. Unlike cisplatin, carboplatin is associated with myelosuppression but
carries a much lower risk of nephrotoxicity or neurotoxicity (31).
The efficacy of platinum-based chemotherapy has since been demonstrated in
several trials. An early meta-analysis by Aabo et al studied 37 trials containing a total of
5667 patients. There was no significant difference in cisplatin compared with carboplatin
(HR 1.02, p = 0.74). Adding platinum to a chemotherapy regimen improved overall
survival by 5% at both 2 (45-50%) and 5 (25-30%) years (HR = 0.88, p = 0.02) (34).
Numerous randomized trials have also demonstrated that carboplatin and paclitaxel
provide a survival benefit equivalent to cisplatin and paclitaxel, but with fewer side
effects (35) (36) (37).

Platinum Resistance
While some patients are platinum resistant, developing recurrence within 6
months of treatment, the majority of patients initially respond to platinum-based therapy
but ultimately develop resistance (38). Among platinum-sensitive patients, who by
definition recur more than 6 months after the end of treatment, the time to recurrence also
has a significant impact on response to additional platinum based chemotherapy (39). A
study by Gore et al found that while 53% (10/19) patients who recurred more than 18
months after the end of treatment responded to additional platinum-based treatment, only
17% (6/35) of patients who recurred within 18 months after the end of therapy had a
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significant response (p = 0.006) (40). There was also a significant difference in median
overall survival between the two groups (486 days for patients who recurred after 18
months vs. 221 days for patients who recurred within 18 months, p = 0.026). There is no
standard second line therapy, and treatment approaches need to be individualized based
on clinical factors. An improved understanding of the biologic differences in tumor
behavior would allow subsequent treatments to have a more rational approach (41) (42)
(43).
Interestingly, BRCA1 or BRCA2 mutant ovarian cancers are more sensitive to
platinum-based chemotherapy. A matched case-control study found that ovarian cancer
patients with BRCA mutations were more likely to respond to platinum based
chemotherapy - - 81.8% of BRCA-positive patients had a complete response, compared to
43.2% of nonhereditary EOC patients (Fisher’s exact test P = 0.004). BRCA patients also
had a higher rate of response to second- and third-line therapies. This difference in
platinum sensitivity in turn impacts overall survival. A multivariate Cox regression
model which controlled for factors such as stage and age at diagnosis demonstrated a
significantly higher risk of death in patients with nonhereditary EOC compared to BRCA
mutant EOC patients (HR 4.539, 95% CI 1.83 – 11.24, p = 0.001) (44).

Neoadjuvant chemotherapy
Neoadjuvant chemotherapy has typically been applied to patients whose medical
comorbidities prevent surgery or to patients whose disease burden is too substantial for
optimal cytoreduction. These patients have similar overall and progression-free survival
compared to patients who undergo the standard regimen of cytoreductive surgery
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followed by chemotherapy (45). A retrospective analysis by Schwartz et al also found
similar progression-free and overall survival in patients with intra-abdominal disease who
received neoadjuvant chemotherapy compared to the standard regimen. This is
significant because patients who received neoadjuvant chemotherapy tend to have a
poorer performance status and a higher disease burden at the time of diagnosis (46).
Other studies have demonstrated improved overall survival in patients receiving
neoadjuvant chemotherapy (47) (48). Kuhn et al demonstrated that patients with an
ascites volume of over 500ml who received neoadjuvant chemotherapy had improved
cytoreduction results (p = 0.04) and overall survival (median overall survival 42 months
vs. 23 months, p = 0.007) (48). A retrospective review by Hou et al noted a statistically
significant difference in progression-free and overall survival in patients with extraabdominal disease who received neoadjuvant chemotherapy compared to patients who
were treated with cytoreductive surgery followed by chemotherapy (49).

MicroRNAs and Cancer
MicroRNAs (miRNAs) are a class of non-protein coding single-strand RNAs ~22
nucleotides in length which negatively regulate multiple gene targets. Since the first
miRNA was discovered in the roundworm Caenorhabditis elegans over fifteen years ago
(50), more than 700 miRNAs have been identified in the human genome. MiRNAs
inhibit gene expression either through the RNAi pathway which leads to mRNA
degradation, or by binding to the 3’ untranslated region (“UTR”) of mRNA and blocking
protein production during translation (51) (52). As miRNAs regulate hundreds of
mRNAs, mutations in the miRNA itself or in its binding site could be associated with
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malignant transformation or disease progression. Oncomirs, which are miRNAs
associated with cancer, may function as tumor-suppressor genes or oncogenes. Tumorsuppressor genes include let-7 in lung cancer, mir-125b in breast cancer, and miR-15a in
B cell chronic lymphocytic leukemia (53). Oncogenes include miR-155 in breast cancer
(54), miR-21 in glioblastoma (55), and miR-155 in Burkitt and Hodgkin lymphoma (56).
In addition, miRNAs have been found to predict prognosis, as well as response to therapy
(57) (53).
The miRNA let-7 family, which functions as tumor suppressors, negatively regulates
the RAS pathway and HMGA2 (58). Deregulation of the let-7 family occurs in several
cancers, including lung, colon, breast, ovarian, pancreatic, and prostate (59).

KRAS-variant
The let-7 family of miRNAs acts as tumor suppressors. It has been demonstrated in
lung cancer that let-7 is reduced in cancer tissue, and RAS is elevated (60). The Weidhaas
lab previously identified a germline single nucleotide polymorphism, rs61764370, in the
let-7 complementary site 6 in the KRAS 3’ UTR region (61). To assess the impact of the
KRAS-variant on KRAS expression, A549 cells, a lung cancer cell line, were transfected
with a luciferase reporter containing the KRAS-variant in the KRAS 3’ UTR and with a
luciferase reporter containing the wild-type KRAS 3’UTR. There was increased KRAS
expression in the cells transfected with the KRAS variant than in cells transfected with the
wild-type KRAS 3’ UTR. Therefore, the KRAS-variant disrupts the binding of let-7 to
KRAS, leading to increased KRAS expression.
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The frequency of the variant allele (referred to as the KRAS-variant) was 18.1 –
20.3% in NSCLC patients compared to 5.3% in healthy controls from 46 world
populations. Moreover, in patients with a moderate smoking history, defined as less than
41 pack years, the KRAS-variant was associated with a 1.4 - 2.3 fold increased risk of
NSCLC (OR 1.4, CI 1.1 – 1.7, p = 0.01; OR 2.3, CI 1.1 – 4.6, p = 0.02) (61).
The KRAS-variant has also been shown to predict outcome and response to therapy in
other cancers. In patients with oral squamous cell cancers, the KRAS-variant was a
statistically significant predictor for reduced overall survival (HR 2.7, 95% CI 1.4 – 5.3)
(62). Among patients with irinotecan-refractory metastatic colorectal cancer treated with
anti-epidermal growth factor inhibitor therapy, overall survival and progression-free
survival were both significantly decreased in patients with the KRAS-variant (63).

The KRAS-variant and Ovarian cancer
In ovarian cancer, miRNA expression patterns can distinguish between not only
cancer tissue and ovarian tissue, but also different ovarian cancer histotypes (64).
MiRNAs were also shown to alter response to treatment - - specifically, upregulation of
mir-214, which targets PTEN, was associated with cisplatin resistance. Decreasing levels
of mir-214 rendered the cancer cells susceptible to cisplatin in vitro (65).
Given the importance of KRAS in solid tumors, several cancer populations were
tested for the KRAS-variant. The KRAS-variant was present in 25% of patients with
epithelial ovarian cancer, compared to less than 18% in control populations or other
cancerous populations with solid tumors. Case control analyses also demonstrated an

10

increased ovarian cancer risk in KRAS-variant patients (OR 2.46, CI 1.14 – 5.29, p =
0.020) (66).
To further assess the impact of the KRAS-variant on ovarian cancer risk, ovarian
cancer patients with a family history consistent with hereditary breast and ovarian cancer
syndrome (“HBOC”) were tested. In addition to their own histories of ovarian cancer,
HBOC patients have at least one other case of ovarian or breast cancer in a first- or
second- degree relative. Patients who tested negative for the BRCA1 or BRCA2 mutation
were classified as “uninformative” HBOC patients. There was a lower frequency of the
KRAS-variant in BRCA1 and BRCA2 HBOC patients compared to uninformative patients.
Indeed, the KRAS-variant was present in 61% of the uninformative patients with ovarian
cancer, a frequency which was significantly higher than in ovarian cancer patients
without a family history (p < 0.001) (66).
The family profiles of KRAS-variant patients were also different than BRCA1- or
BRCA2- patients. Specifically, the patients in KRAS-variant HBOC families were more
likely to be older at the time of diagnosis, non-Jewish, and to have a family history of
lung cancer. As such, the KRAS-variant represents a new mechanism for identifying
patients at elevated risk of epithelial ovarian cancer.

Summary
In summary, epithelial ovarian cancer continues to have a poor overall prognosis
despite aggressive surgery and chemotherapy regimens. The KRAS-variant is an
important new predictor of ovarian cancer risk. Given its prevalence in EOC, we
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hypothesize that the KRAS-variant also impacts overall survival and response to
platinum-based chemotherapy.
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Statement of Purpose
This project will assess the impact of the 3’UTR KRAS-variant on overall survival
and response to platinum-based chemotherapy in ovarian cancer.
First, we will statistically compare overall survival in KRAS-variant and wild-type
non-BRCA mutant ovarian cancer patients in both univariate and multivariate analyses.
We hypothesize that patients with the KRAS-variant will have reduced overall survival
compared to wild-type patients.
Second, we will statistically compare the overall survival of BRCA mutant
patients. An association between the KRAS-variant and BRCA1 EOC patients has been
previously noted (66). To control for this difference between BRCA1 and BRCA2 EOC
patients, we will assess survival of each group separately as well. Of note, BRCA
mutants typically have improved response to platinum based chemotherapy. Therefore,
although we hypothesize that patients with the KRAS-variant will have reduced overall
survival; this result may not be as significant as the difference in survival in non-BRCA
mutant patients.
Third, we will assess response to platinum-based chemotherapy in KRAS-variant
patients and wild-type patients by comparing the rate of optimal cytoreduction in patients
who received neoadjuvant chemotherapy. We hypothesize that patients with the KRASvariant will have a higher rate of suboptimal cytoreduction when controlling for age,
stage, histology, and grade.
Fourth, we will compare the rate of platinum resistance in KRAS-variant and wildtype EOC patients who received the standard therapy of cytoreductive surgery followed
by adjuvant platinum-based chemotherapy. We hypothesize that KRAS-variant patients
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will have a higher rate of platinum resistance, defined as recurrence within 6 months of
completion of chemotherapy. We also propose that KRAS-status will be a significant
predictor of platinum resistance in a multivariate regression controlling for residual
disease, age, stage, grade and tumor histology.
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Methods
Survival analysis cohorts
Clinical data and DNA from women diagnosed with invasive epithelial ovarian
cancer without known BRCA mutations were included from the following three
institutions under individual IRB approvals: 1) Yale New Haven Hospital (n=194); 2)
Turin, Italy #1 (n=198) (67); 3) Brescia, Italy #2 (n=59) (66). Patients diagnosed
between 1998 and 2009 were included in the analysis. Information was collected on
patient demographics, including age, race, and family history, as well as pathologic data
such as stage, grade, and histology. Patients with unknown tumor histology were
excluded from the analysis, as it was not possible to rule out the presence of a borderline
tumor in those patients.
Documented BRCA mutant epithelial ovarian cancer cases were collected from
the following two cohorts: 1) Yale New Haven Hospital (n=17); 2) City of Hope
Comprehensive Cancer Center (n=62). As BRCA1 and BRCA2 mutations have been
shown to independently influence survival in ovarian cancer, we evaluated the impact of
the KRAS-variant on these groups separately.
As not all Stage I ovarian cancer patients receive chemotherapy, and substage
information was not available for patients with Stage I tumors, these patients were
excluded from the overall survival analyses for both non-BRCA and BRCA mutant
patients. Only patients treated with chemotherapy were included in this analysis. We
included women treated with neoadjuvant chemotherapy, and counted date of
pathological diagnosis as the start date.
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A total of 451 patients with wild type BRCA or not tested for BRCA mutations and
79 patients with documented BRCA mutations were included in the survival analyses.
Overall survival time was measured as time from primary cytoreductive surgery or first
administration of chemotherapy, whichever was earlier, to date of death or last visit.

Neoadjuvantly treated ovarian cancer patients
An IRB-approved review of the pathologic and treatment records from Yale New
Haven Hospital between 1996 and 2010 was done to identify women with epithelial
ovarian cancer treated with neoadjuvant chemotherapy followed by cytoreductive surgery
(n=122). This cohort of patients received chemotherapy as a primary treatment due to
tumor burden that was too extensive for optimal surgical debulking at presentation. Only
patients diagnosed between 1998 and 2009 and treated with six cycles of carboplatin and
paclitaxel were included in this analysis. Following chemotherapy, patients underwent
cytoreductive surgery and additional adjuvant treatment. The following information was
collected for these patients: age, race, ethnicity, BRCA status, family history,
chemotherapy given prior to surgery, surgery performed, residual disease after surgery,
stage, tumor histology, histologic grade and subsequent adjuvant chemotherapy. Optimal
cytoreduction was defined as residual disease measuring less than 1cm remaining after
surgery, while suboptimal cytoreduction was defined as residual disease measuring
greater than or equal to 1cm at the completion of surgery. Only women operated on at
Yale New Haven Hospital by the same group of surgeons were included, to avoid bias in
surgical skill as a factor impacting residual disease.
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Patients for analysis of platinum resistance
Platinum resistance was defined as progression-free survival (PFS) of less than 6
months from the completion of platinum containing adjuvant chemotherapy to the date of
recurrence. The progression-free survival interval was available for women from three
groups of patients: Italy #1, Italy #2, and Yale-New Haven Hospital patients (n=292),
which included some of the patients analyzed for survival with additional patients who
were not included in that analysis. This cohort underwent surgical staging and
cytoreductive surgery prior to treatment with platinum-based chemotherapy. The
following information was collected for these patients: age at diagnosis, KRAS-variant
status, stage at diagnosis, histology, grade, progression-free survival, and date of death or
last visit. Importantly, information on residual disease following cytoreductive surgery
was also analyzed.

DNA Extraction
As previously shown by Chin et al, the KRAS-variant does not appear to be
somatically acquired nor does it require a loss of heterozygosity. As such, DNA samples
could be collected from tumor, blood or sputum samples. DNA extraction was
performed at each institution using the techniques described below.
At Yale, DNA extraction was performed by FK Keane with assistance from S
Nallur. E Ratner and T Paranjape assisted with the collection and processing of fresh
frozen tissue samples.

17

Fixed Formalin Paraffin Embedded (“FFPE”) tissue samples
FFPE samples were provided by the Yale New Haven Hospital Department of
Pathology. DNA was isolated from FFPE tissue samples using the Ambion
RecoverAllTM kit. First, 1 ml 100% Xylene was added to the sample and incubated in a
50°C water bath for 3 minutes. The sample was centrifuged at maximum speed for 2
minutes, the xylene was discarded, and the pellet was washed twice with 1 ml of 100%
ethanol. After the pellet was air dried for 1 hour, 200 ul of Digestion Buffer and 4 ul of
Protease were added. The entire sample was incubated overnight in a 50°C water bath.
Following incubation, an Isolation Additive/ ethanol mixture consisting of 240ul of the
Isolation Additive and 550 ul 100% ethanol was added to each sample. A filter cartridge
was placed in a collection tube, and then 700ul of the sample was pipetted onto the filter
cartridge. The tube was centrifuged at 10,000xg for 30 seconds, and the flow through was
discarded. The remaining volume of the sample solution was added to the filter cartridge,
centrifuged at 10,000xg for 30 seconds and the flow-through was discarded. The filter
cartridge was washed with 700ul of Wash 1, centrifuged at 10,000xg for 30 seconds, and
the flow-through was discarded. Next, 500ul of Wash 2/3 was added to the filter
cartridge, centrifuged, and the flow through was discarded. The filter cartridge and
collection tube were centrifuged for an additional 30 seconds and the remaining flowthrough was discarded. Next, the filter cartridge was transferred to a new collection tube,
and 60ul of Elution Solution preheated to 95°C was added to the cartridge, incubated at
room temperature for 1 minute and then centrifuged at maximum speed. The sample was
stored at -20°C.
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Fresh Frozen Tissue samples
Fresh frozen tissue samples were collected and ground with a pestle in a 1.5ml
tube while on dry ice. Next, 180ul of Buffer ATL was added followed by 20 ul Proteinase
K. The sample was vortexed and incubated in a 56°C water bath for approximately 2
hours until all tissue was lysed. The sample was vortexed for 15 seconds, a 400ul 50:50
mixture of Buffer AL and 100% ethanol was added, and the sample was vortexed again.
The mixture was pipetted onto a DNeasy Midi spin column in a collection tube, and then
centrifuged for 1 minute at 8000rpm. The flow through and collection tube were both
discarded after this step, as well as the Buffer AW1 and Buffer AW2 steps. After 500ul
Buffer AW1 was added, the sample was centrifuged at 8000rpm for 1 minute. Next,
500ul Buffer AW2 was added to the column and the sample was centrifuged at 14000rpm
for 3 minutes. The column was placed in a 1.5ml tube and 200ul Buffer AE was added to
the column. After incubating at room temperate for 1 minute, the tube was centrifuged at
8000rpm for 1 minute. The column was discarded and the eluate was stored at -20°C.

Sputum samples
Sputum samples were collected using the Oragene-DNA kit and processed
according to DNA Genoteck instructions. Sputum samples were stored with the
Oragene-DNA solution after collection and were incubated overnight in a 50°C water
bath prior to processing. Following incubation the entire sample was transferred to a 15
ml centrifuge tube. A volume of Oragene-Purifier (equivalent to 1/25th of the original
sample) was added and mixed by vortexing for 10 seconds. The sample was incubated
on ice for 10 minutes and then centrifuged for 20 minutes at a speed of 4,000xg. The
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supernatant was transferred to a fresh tube and the pellet was discarded. An equal volume
of 100% ethanol was added to the supernatant and mixed by inversion. Following
incubation at room temperature for 10 minutes the sample was centrifuged for 15 minutes
at a speed of 4,000xg. The supernatant was removed and discarded and 250ul of 70%
ethanol was added to the pellet. After standing at room temperature for 1 minute, the
ethanol was removed. The pellet stood at room temperature for approximately 1 hour.
The DNA was rehydrated by adding 300 – 500ul of TE solution and then transferred to a
1.5ml tube. The sample remained at room temperature overnight and then was stored at 20°C.

Blood samples
Finally, DNA was extracted from blood samples using the QIAamp Blood Midi
Kit. Each blood sample was divided and processed in two batches. First, 200ul Qiagen
Protease was added to a 15ml centrifuge tube. Between 1 and 2 ml of blood were added
to each tube and mixed by inversion. Following the addition of 2.4ml of Buffer AL, each
tube was inverted 15 times and then shaken for 1 minute. After the sample was incubated
in a 70°C water bath for 10 minutes, 2 ml 100% ethanol was added and the tube was
inverted 10 times. Half of the sample pipetted onto a QIAamp Midi Column in a 15 ml
centrifuge tube. The tube was centrifuged at 1850xg for 3 minutes, the flow-through was
discarded, and the remaining half was added to the column. The sample was centrifuged
again at 1850xg for 3 minutes and the flow-through was discarded. After 2ml of Buffer
AW1 was added to the column, the sample was centrifuged at 4500xg for 1 minute. 2ml
Buffer AW2 was added to the column and then the sample was centrifuged at 4500xg for
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15 minutes. The column was placed in a new 15ml tube, and 300ul Buffer AE was added.
After incubating at room temperature for 5 minutes, the sample was centrifuged at
4500xg for 2 minutes. The column was discarded and the eluate was stored at -20°C.

Detection of the KRAS-variant
The variant allele was detected using a primer specific to the KRAS-variant and a
TaqMan PCR assay. First, 50-60ng of DNA in 9 ul dH2O was added to the wells of a
96-well plate. DNA from at least two known heterozygous variant, homozygous variant
and homozygous wild-type samples were included on each plate. A master mix was
prepared with 10ul of Taqman® Genotyping Master Mix for every 1ul of Taqman probe.
Next, 11ul of this master mix was added to each well of the 96 well plate. The plate was
centrifuged at 3000rpm for 1 minute and then run on the Applied Biosystems 7900HT
Real-Time PCR System. Less than 3% of populations carry two copies of the variant
(61). As such, patients who carried at least one copy of the variant allele were classified
as KRAS-variant carriers. Assays were performed by FK Keane with guidance from T
Paranjape.

Statistics
To assess the significance of demographic variables, a χ2 test or a two-sided
Fishers’s exact test was used for categorical variables. A t test was used for continuous
variables, such as age and follow-up time.
The overall survival time of KRAS-variant and wild-type patients was compared
using the Kaplan-Meier method (68), and the statistical significance of the survival
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curves was determined by the log-rank test (69). A Cox proportional hazards regression
model (70) was used to assess the impact of the KRAS-variant and demographic and
prognostic variables, including age, stage, grade, and histology, on overall survival.
Multivariate logistic regression analyses (71) were used to determine the impact
of the KRAS-variant and other demographic and prognostic factors on the probability of
suboptimal cytoreduction. Multivariate logistic regression analyses (71) were used to
assess the association of the KRAS-variant and other prognostic factors on the probability
of platinum resistance.
The statistical analyses described above were performed by F.K. Keane using
SAS 9.1.3 (SAS Institute Inc., Cary, NC) with guidance from Lingeng Lu and Yanhong
Deng.
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Results
Survival in KRAS-variant positive EOC patients
We evaluated the association of the KRAS-variant with overall survival in EOC
patients who had received surgery and platinum-based chemotherapy (n=451). The
clinicopathologic parameters for this cohort are presented in Table 1.

Table 1. Clinicopathologic parameters for non-BRCA mutant EOC patients
Variable name
Wild type
KRAS variant
P value
(n=348)
(n=103)
Age (standard deviation)
60.44 (11.97)
58.77 (11.59)
0.2144
Stage
1
2
3
4
Unknown
Grade
Well differentiated
Moderately differentiated
Poorly differentiated
Unknown
Histology
Serous
Endometrioid
Undifferentiated
Clear Cell
Mucinous
Carcinosarcoma
Mixed
Unknown
Center
Yale New Haven Hospital
Italy #1
Italy #2
Follow up Time in months

0.7747
52 (14.94)
21 (6.03)
194 (55.75)
78 (22.41)
3 (0.86)

15 (14.56)
6 (5.83)
52 (50.49)
29 (28.16)
1 (0.97)

29 (8.33)
60 (17.24)
228 (65.52)
31 (8.91)

14 (13.59)
8 (7.77)
74 (71.84)
7 (6.80)

0.0420

0.2230
202 (58.05)
37 (10.63)
7 (2.01)
21 (6.03)
17 (4.89)
13 (3.74)
20 (5.75)
31 (8.91)

52 (50.49)
16 (15.53)
0 (0.00)
10 (9.71)
2 (1.94)
7 (6.80)
6 (5.83)
10 (9.71)

156 (44.83)
147 (42.24)
45 (12.93)
38.84 (30.17)

38 (36.89)
51 (49.51)
14 (13.59)
35.96 (29.45)

0.3417
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0.3924

Because we have previously found that the KRAS-variant is not associated with
early onset EOC, we evaluated the impact of the KRAS-variant on survival in women
who developed EOC over the age of 55 (n=248). For this subset of EOC patients overall
survival was significantly reduced in KRAS-variant positive patients compared to variant
negative patients as shown by Kaplan-Meier curves (Figure 1, median survival of 30.00
months in KRAS-variant patients, vs. median survival of 58.50 months in wild-type
patients, log rank p = 0.0103).

Figure 1: The KRAS-variant predicts significantly worse overall survival for
epithelial ovarian cancer patients over 55 years-old. Overall survival for ovarian
cancer patients with and without the KRAS-variant is compared using Kaplan Meier
curves. There is significantly worse outcome for KRAS-variant positive ovarian cancer
patients. Log rank p = 0.0103
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The KRAS-variant was also a predictor of poor outcome for women over 55 yearsold in a Cox proportional hazards multivariate model (Table 2, KRAS-variant HR = 1.71,
95% CI=1.09 – 2.69, p = 0.0204).

Table 2: The KRAS-variant Predicts Worse Survival for Ovarian Cancer Patients
over 55 years-old
Variable
HR
95% CI
p value
1.71
1.09 – 2.69
0.0204
KRAS status
1.57
1.13 – 2.18
0.0078
Stage
HR: hazards ratio obtained from Cox proportional Hazards multivariate analysis
CI: confidence interval
Studies Included: Yale New Haven Hospital, Italy #1, Italy #2
Note: Age, Grade, and Histology were not statistically significant and were therefore
excluded from the final analysis.

Survival in KRAS-variant BRCA positive EOC patients
We evaluated the impact of the KRAS-variant on survival in EOC patients
carrying deleterious BRCA1 or BRCA2 mutations. Clinicopathologic parameters for
these patients are presented in Table 3.
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Table 3. Clinicopathologic parameters for BRCA mutant EOC patients
Variable name
Wild type (n=69) KRAS variant (n=10)
Age
52.77 (10.20)
52.60 (12.47)
Stage
1
5 (7.25)
2 (20.00)
2
8 (11.59)
2 (20.00)
3
51 (73.91)
5 (50.00)
4
5 (7.25)
1 (10.00)
Grade
Well differentiated
2 (2.90)
1 (10.00)
Moderately differentiated 13 (18.84)
1 (10.00)
Poorly differentiated
49 (71.01)
8 (80.00)
Unknown
5 (7.25)
0 (0.00)
BRCA status
BRCA 1
51 (73.91)
7 (70.00)
BRCA 2
18 (26.09)
3 (30.00)
Center
Yale New Haven Hospital 16 (23.19)
1 (10.00)
City of Hope
53 (76.81)
9 (90.00)
Note: Histology information was not available for City of Hope patients

P value
0.9623
0.1771

0.5275

0.7206

0.6808

There was no significant difference in survival between those with and without
the KRAS-variant in a multivariate analysis using a Cox proportional hazards model
(Table 4, KRAS-variant HR = 0.99, 95% CI: 0.28-3.56, p = 0.99). However, the number
of patients available for the analysis was low (n=79). Because we had previously seen an
association of the KRAS-variant with BRCA1 but not BRCA2 mutations, we evaluated the
impact of the KRAS-variant on survival separately for EOC patients with BRCA1
mutations. Again there was no significant difference in survival in KRAS-variant positive
versus negative patients in a multivariate analysis using a Cox proportional hazards
model (KRAS-variant HR = 0.61, 95%CI: 0.14-2.76, p = 0.52). There were too few
patients with BRCA2 mutations for analysis.
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Table 4: The KRAS-variant and Overall Survival in BRCA mutant patients
Variable
HR
95% CI
P value
All BRCA mutant patients (n = 72)
0.994
0.28 – 3.56
0.9921
KRAS status
1.028
0.996 – 1.06
0.0832
Age
3.369
1.475 – 7.691
0.0039
Stage
BRCA1 mutant patients (n = 54)
0.610
0.14 – 2.76
0.5202
KRAS status
3.748
1.43 – 9.80
0.0071
Stage
HR: hazards ratio obtained from Cox proportional Hazards multivariate analysis
CI: confidence interval
Studies Included: Yale New Haven Hospital, City of Hope

The KRAS-variant and response to neoadjuvant chemotherapy
To gain insight into the cause of the worse survival in KRAS-variant positive
ovarian cancer patients, we evaluated the impact of KRAS-variant positivity on response
to platinum chemotherapy. We included women with EOC who were treated at YaleNew Haven Hospital with neoadjuvant chemotherapy followed by surgical cytoreduction
(n = 122), and used residual disease after surgery (cytoreduction) as a marker of patient
response to neoadjuvant carboplatin and paclitaxel chemotherapy. The KRAS-variant
allele was present in 22.13% of patients, a frequency which is similar to the prevalence of
the KRAS-variant in EOC noted by Ratner et al (66). The mean ages of the KRAS-variant
patients (n=27) and the wild-type (non-KRAS-variant) patients (n=95) were similar (62.67
± 13.57 years old vs. 63.84 ± 12 years old in wild-type patients), and the majority of the
patients were Caucasian (96.3% of KRAS-variant patients vs. 92.6% of wild-type
patients). More KRAS-variant patients were classified as Stage IV compared to wild-type
patients (85.2% vs. 53.7%, p=0.01). Complete clinicopathologic parameters of patients
who received neoadjuvant chemotherapy are presented in Table 5.
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Table 5. Clinicopathologic parameters of patients receiving neoadjuvant
chemotherapy
Variable name
Wild type
KRAS variant
(n=95)
(n=27)
Age (standard deviation)
63.84 (12.00)
62.67 (13.57)

P VALUE

Race

0.6832

Caucasian
Other
Stage
2
3
4
Unknown
Grade
Well differentiated
Moderately differentiated
Poorly differentiated
Unknown
Histology
Serous
Endometrioid
Undifferentiated
Clear Cell
Mucinous
Carcinosarcoma
Mixed
Unknown
Neoadjuvant Chemotherapy
Carboplatin/ Paclitaxel
Carboplatin/ Taxotere
Carboplatin/ Cyclophosphamide
Other
Neoadjuvant cycles completed:
2
3
4
5
6
7
9
Follow up time

88 (92.63)
7 (7.37)

26 (96.30)
1 (3.70)

1 (1.05)
42 (44.21)
52 (53.68)
1 (1.05)

0 (0.00)
4 (14.81)
23 (85.19)
0 (0.00)

0.6636

0.0106

0.1923
2 (2.11)
12 (12.63)
69 (72.63)
12 (12.63)

0 (0.00)
0 (0.00)
24 (88.89)
3 (11.11)

72 (75.79)
2 (2.11)
3 (3.16)
4 (4.21)
1 (1.05)
1 (1.05)
5 (5.26)
7 (7.37)

18 (66.67)
0 (0.00)
0 (0.00)
2 (7.41)
0 (0.00)
1 (3.70)
3 (11.11)
3 (11.11)

83 (88.87)
1 (1.05)
8 (8.42)
3 (3.16)

20 (74.07)
1 (3.70)
5 (18.52)
1 (3.70)

2 (2.11)
4 (4.21)
17 (17.89)
3 (3.16)
66 (69.47)
2 (2.11)
1 (1.05)
31.54 (27.52)

0 (0.00)
2 (7.41)
2 (7.41)
4 (14.81)
19 (70.37)
0 (0.00)
0 (0.00)
37.22 (36.56)

0.6138

0.2014

0.2328
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0.3834

Optimal cytoreduction was defined as less than 1cm of residual disease remaining
at the completion of surgery, and suboptimal cytoreduction was defined as greater than
1cm of residual disease left at the completion of surgery. We found that 20.0% of KRASvariant patients were suboptimally cytoreduced, compared with only 2.0% of wild-type
patients (Figure 2).

120.0%
% of patients

100.0%
80.0%

optimal debulking
(RD < 1cm)

60.0%

suboptimal debulking
(RD > 1cm)

40.0%
20.0%
0.0%
KRAS wild type

KRAS-variant

KRAS - variant status

Figure 2: Surgical debulking in Stage III and IV patients treated with six cycles of
neoadjuvant carboplatin and paclitaxel

The KRAS-variant was significantly associated with residual disease greater than
1 cm (suboptimal cytoreduction) after neoadjuvant chemotherapy and surgery in a
multivariate logistic regression controlling for age and histology (Table 6, OR = 26.27,
95% CI: 1.56 – 441.83, p = 0.0232).
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Table 6. The KRAS-variant Predicts Suboptimal Debulking after Neoadjuvant
Chemotherapy
Univariate
Multivariate3
KRAS-variant
Genotype
OR1
95% CI2
p
OR
95% CI

p

All
1.00
Wild-type (n=58)
14.25
1.36 – 149.01
Variant (n=15)
1. OR: odds ratio obtained from logistic regression
2. CI: confidence interval
3. Multivariate: adjusted for age and histology.

0.027

1.00
26.27

1.56 – 441.83

The KRAS-variant is associated with platinum resistance
To better evaluate if the increase in residual disease after neoadjuvant carboplatin
and paclitaxel chemotherapy seen in KRAS-variant positive EOC patients was due to
chemotherapy resistance and not simply desmoplasia of the tumors, we directly assessed
platinum resistance in adjuvantly treated EOC patients with known KRAS-variant status
(n=292). The median ages of the KRAS-variant patients (n=68) and the wild-type
patients (n=224) were similar (56.97 ± 10.21 years old vs. 58.83 ± 11.87 years old in
wild-type patients). The majority of both KRAS-variant and wild-type patients had Stage
III or Stage IV disease (69.1% vs. 69.6% in wild-type patients). Importantly, we found
that in this cohort, optimal cytoreduction before chemotherapy was no different between
KRAS-variant positive and wild-type patients (60.29% vs. 59.24%). Complete
clinicopathologic parameters for patients included in the platinum resistance analysis are
presented in Table 7.
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0.0232

Table 7. Clinicopathologic parameters for platinum resistance analysis
Variable name
Wild type
KRAS variant
P VALUE
(n=224)
(n=68)
Age
58.83 (11.87)
56.97 (10.21)
0.1179
Stage
1
2
3
4
Grade
Well differentiated
Moderately differentiated
Poorly differentiated
Unknown
Histology
Serous
Endometrioid
Undifferentiated
Clear Cell
Mucinous
Carcinosarcoma
Mixed
Unknown
Platinum response
Sensitive
Resistant
Cytoreductive surgery
Optimal cytoreduction
(<1cm residual disease)
Suboptimal cytoreduction
(>1cm residual disease)
Unknown
Center
Yale New Haven Hospital
Italy #1
Italy #2
Follow up Time

0.9830
49 (21.88)
19 (8.48)
134 (59.82)
22 (9.82)

16 (23.53)
5 (7.35)
40 (58.82)
7 (10.29)
0.1593

27 (12.05)
42 (18.75)
140 (62.50)
15 (6.70)

14 (20.59)
8 (11.76)
44 (64.71)
2 (2.71)

107 (47.77)
36 (16.07)
27 (12.05)
14 (6.25)
19 (8.48)
11 (4.91)
9 (4.02)
1 (0.45)

29 (42.65)
15 (22.06)
7 (10.29)
8 (11.76)
2 (2.94)
5 (7.35)
1 (1.47)
1 (1.47)

210 (93.75)
14 (6.25)

58 (85.29)
10 (14.71)

0.2746

0.0262

0.1115
125 (55.80)

41 (60.29)

86 (38.39)

27 (39.71)

13 (5.80)

0 (0.00)

44 (19.64)
147 (65.63)
33 (14.73)
44.33 (35.24)

7 (10.29)
51 (75.00)
10 (14.71)
34.35 (22.33)

0.1934

0.0283

Platinum resistance, defined as disease recurrence within 6 months of receiving
platinum based chemotherapy, was significantly more prevalent in KRAS-variant carriers
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than in wild-type patients (14.71% vs. 6.25%, p < 0.0307). The KRAS-variant was a
statistically significant predictor for platinum resistance in a multivariate logistic
regression analysis controlling for residual disease remaining after cytoreductive surgery,
stage, and grade (Table 8, OR = 2.86, 95% CI: 1.13 – 7.23, p = 0.0264).

Table 8. The KRAS-variant Predicts Platinum resistance
Univariate
KRAS-variant
1
Genotype
OR
95% CI2
p

OR

Multivariate3
95% CI

p

1.00
2.86

1.13 – 7.23

0.0264

All
1.00
Wild-type (n=224)
2.59
1.09 – 6.12
0.0307
Variant (n=68)
1. OR: odds ratio obtained from logistic regression
2. CI: confidence interval
3. Multivariate: adjusted for stage, grade, and residual disease
Studies: Yale, Italy #1, Italy #2
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Discussion
Our data supports the hypothesis that the KRAS-variant is associated with reduced
overall survival in EOC patients who do not carry a BRCA mutation, as well as a higher
risk of suboptimal cytoreduction and platinum resistance. There was no significant
difference in survival among BRCA patients, although this will need to be confirmed with
a larger patient cohort.
Although the association of the KRAS-variant with risk of EOC is strongest in
patients from high-risk breast and ovarian cancer families(66), our data demonstrates that
the KRAS-variant is an important marker of poor survival in nonhereditary EOC patients,
as well.

Overall Survival in non-BRCA mutant patients
The identification of reduced overall survival in nonhereditary EOC patients
represents an important step in the understanding of the role of the KRAS-variant.
Indeed, the KRAS-variant was a significant predictor of reduced overall survival in
patients over 55 years old in both a Kaplan-Meier analysis and in a Cox proportional
hazards multivariate analysis controlling for stage. Age, grade and histology were not
significant predictors of reduced overall survival by the Cox proportional hazards model
and were therefore excluded from the final analysis.
The significant association of the KRAS-variant with poor survival for women
over age 55 may be due to the unintentional inclusion of BRCA mutant patients or
patients with non-epithelial tumors in the larger cohort of ovarian cancer patients studied,
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both of whom would most likely be found in the group of women diagnosed under the
age of 55.
Alternatively, these findings may instead reflect some true underlying biology of
the KRAS-variant, which appears not to be associated with early onset tumors, and may
instead be affected or accelerated by the aging process. The association of the KRASvariant with diagnosis at older age was previously demonstrated in non-BRCA mutant
HBOC families (66). This hypothesis requires additional validation. Of note, given the
reduced survival of patients with the KRAS-variant, it is important for case-control
studies to avoid delays in patient enrollment. Significant delays would likely lead to
inadvertent underrepresentation of patients with the KRAS-variant.

Overall Survival in BRCA mutant patients
The KRAS-variant did not predict for reduced survival in BRCA mutant patients.
In both a univariate analysis and a Cox proportional hazards multivariate regression
controlling for age and stage there was no significant difference in the risk of death. This
may be secondary to the low sample size. However, this observation may also reflect the
fact that BRCA mutations are associated with platinum-sensitivity (44) and this effect
may be downstream of any resistance caused by the KRAS-variant to platinum agents.
Studies are underway to determine if the KRAS-variant predicts altered resistance to other
chemotherapeutic agents in the background of BRCA mutations.
Of note, there were no BRCA2 patients with the KRAS-variant who died during
the analysis period. This precluded a comparison of overall survival in BRCA2 patients
through a Kaplan-Meier analysis.
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Response to neoadjuvant chemotherapy
Our data demonstrated that KRAS-variant patients were more likely to be
suboptimally cytoreduced than wild-type patients. Importantly, all patients included in
this analysis had received six cycles of platinum-based combination chemotherapy prior
to neoadjuvant surgery. Furthermore, the surgeries were all performed by gynecologic
oncologists at Yale New Haven Hospital. This is important for two reasons. First,
patients who are operated on by a gynecologic oncologist instead of a gynecologist or a
general surgeon have improved overall survival (72) (73). This difference is likely due to
more accurate surgical staging by gynecologic oncologists (21) as well as an increased
likelihood of optimal surgical debulking (73) (74). General surgeons who have not
received training in cytoreductive surgery tend to achieve optimal cytoreduction in 25%
or less of cases (75) (27). By contrast, gynecologic oncologists at tertiary care centers
have been shown to achieve optimal cytoreduction in up to 76% of cases (76) (77). Of
note, these studies defined optimal cytoreduction as less than 2cm of residual disease
remaining at the end of cytoreductive surgery. The acceptable level of residual disease
for optimal cytoreduction has since been revised to less than or equal to 1cm. The
current standard of 1cm was used to evaluate cytoreduction in our analysis.
Second, even in a tertiary care setting, optimal debulking varies with surgeon
philosophy - - defined as how frequently a surgeon employs radical procedures such as
diaphragm stripping and bowel resection. In other words, increasing aggressiveness was
associated with a higher rate of optimal debulking (78). By limiting the analysis to
patients treated by one department, Gynecologic Oncology at YNHH, we reduced

35

discrepancies in surgeon philosophy which may have been present if numerous
departments or hospitals were included.
In addition to the above restrictions, we also controlled for age, stage, histology
and grade in a multivariate logistic regression. As such, we were able to accurately
assess the impact of KRAS-status on the rate of optimal cytoreduction. The elevated rate
of suboptimal debulking in KRAS-variant patients compared to wild-type patients raises
questions as to the ideal chemotherapy regimen for KRAS-variant patients. Further study
will be required to determine if patients would benefit from altering the current standard
regimen.

Platinum resistance
The data demonstrated a significant association of the KRAS-variant with
platinum resistance in non-BRCA mutant EOC patients. This association held even when
controlling for stage, grade, and residual disease remaining after cytoreductive surgery.
The risk of platinum resistance, as well as the association of suboptimal cytoreduction
with the KRAS-variant, suggests that the reduced overall survival in KRAS-variant
patients may be secondary to resistance to current chemotherapy regimens.
The current approach to tailor cancer treatment has been to use assays that
measure tumor-acquired mutations to try and predict tumor response to different
therapeutic regimens. This approach is inherently limited by the inability to confirm
which mutations, of which there are many, truly drive tumor biology for an individual’s
tumor.
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By contrast, the germline KRAS-variant appears to lead to biologically and
behaviorally similar tumors, allowing sub-classification of these tumors, and affords the
potential in the near future to use this marker to tailor and optimize patient treatment.
Indeed, several studies have documented the association of polymorphisms with response
to chemotherapy, progression-free survival and overall survival. In colorectal cancer,
polymorphisms in drug metabolism genes have been associated with reduced overall
survival (79) as well as impaired treatment response (80) and toxicity (81). A
retrospective review of NSCLC patients receiving platinum-based chemotherapy
demonstrated that polymorphisms in DNA repair genes were associated with reduced
overall survival (82). Further study will be necessary to determine the ideal
chemotherapy regimen for KRAS-variant EOC patients.

Conclusions
These data demonstrate the potential application of the KRAS-variant as a
biomarker for poor outcome in epithelial ovarian cancer. The poor survival of patients
with the KRAS-variant may be associated with resistance to platinum-based
chemotherapy, as KRAS-variant patients had a significantly higher risk of suboptimal
cytoreduction and platinum resistance. Further understanding of the mechanism of the
KRAS-variant in tumor biology and response to chemotherapy will require additional
work in cancer initiation models, which is ongoing. Regardless, identification of
inherited variants that are biomarkers of outcome is an exciting advance in clinical
oncology and will hopefully lead to more effective treatment options and improved
patient survival.
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